Low-dose Zoladex won’t be available in Australia from November. What might that mean for you?

With the removal of low-dose Zoladex from Australian shelves starting November, patients who rely on it for endometriosis and certain breast cancer treatments may face significant challenges. This change could lead to increased costs and a need for alternative medications, which might not be as effective or could come with different side effects. The decision underscores broader issues in pharmaceutical availability and healthcare access, highlighting the importance of ongoing discussions about drug pricing and availability in medical treatment plans.